drugset / Trial / NCT00722215

Endothelin Receptor Antagonism in Proteinuric Nephropathy

NCT00722215

RandomizedCrossoverTriple-blindBasic science

Summary

The number of people with kidney problems is increasing rapidly, related in part to the increasing prevalence of diabetes. Patients with kidney problems tend to have protein leaking into the urine (proteinuria). Both proteinuria and the kidney disease itself are associated with an increased risk of heart disease. Reducing proteinuria is an important treatment goal in people with kidney problems. Endothelin is a chemical produced both by blood vessels and the kidney. Higher than normal levels of endothelin are thought to contribute to progression of kidney disease and proteinuria. By using drugs that block the effects of endothelin ('endothelin receptor antagonists') we can hopefully reduce both of these. The purpose of the study is to ascertain whether endothelin receptor antagonists improve kidney function and reduce proteinuria more so than other commonly used drugs.

Timeline

Start
2006-05
Primary completion
2007-11
Completion
2007-12

Drugs

EvaluationDrugModalityDoseRoute
Subject BQ-123 Peptide 1000 unknown Intravenous
Comparator Nifedipine Other / unclassified 10 mg Oral